LASA Supergenerics announced its fire-affected manufacturing facility cannot resume operations due to ongoing clearance and operational challenges.

The company is actively exploring alternative solutions, including contract manufacturing arrangements or leasing the facility.

This move aims to mitigate business disruption and ensure continued production.

Investors should note this significant operational shift as the company navigates its path to production recovery.